Budget Amount *help |
¥45,110,000 (Direct Cost: ¥34,700,000、Indirect Cost: ¥10,410,000)
Fiscal Year 2023: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2022: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2021: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2020: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2019: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
|
Outline of Final Research Achievements |
Aiming to elucidate the essential role of humoral immunity in the tumor microenvironment, I utilized single-cell immune repertoire sequencing across various clinical cancer samples, isolating numerous cancer-specific antibodies and beginning to unravel novel molecular mechanisms of humoral tumor immunity. Additionally, I identified that the antigens recognized by the tumor-specific antibodies which I had identified from human cancer environments were "densely-sulfated glycosaminoglycans." Further experiments using a mouse xenograft model demonstrated that such anti-densely-sulfated glycosaminoglycan antibodies exhibited clear anti-tumor effects against multiple cancers, revealing their potential applicability as therapeutic antibodies.
|